- Conditions
- Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Secondary Hyperparathyroidism, End Stage Kidney Disease
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 50
- States / cities
- Anaheim, California • Chula Vista, California • Escondido, California + 43 more